Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Immunic Inc (IMUX)
Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 130,397
  • Shares Outstanding, K 89,929
  • Annual Sales, $ 0 K
  • Annual Income, $ -93,610 K
  • 60-Month Beta 2.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.29
Trade IMUX with:

Options Overview Details

View History
  • Implied Volatility 306.26% ( -79.66%)
  • Historical Volatility 66.52%
  • IV Percentile 78%
  • IV Rank 37.66%
  • IV High 751.46% on 10/31/23
  • IV Low 37.36% on 03/22/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 189
  • Volume Avg (30-Day) 105
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 6,999
  • Open Int (30-Day) 6,204

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.24
  • Low Estimate -0.32
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +53.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1300 +35.40%
on 02/13/24
1.5500 -1.29%
on 03/04/24
+0.3100 (+25.41%)
since 02/02/24
3-Month
1.0900 +40.37%
on 01/11/24
1.7300 -11.56%
on 01/05/24
+0.3500 (+29.66%)
since 12/04/23
52-Week
0.9451 +61.89%
on 11/13/23
3.1100 -50.80%
on 07/05/23
-0.4000 (-20.73%)
since 03/03/23

Most Recent Stories

More News
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.5300 (+5.52%)
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.5300 (+5.52%)
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.5300 (+5.52%)
Stock Index Futures Climb on Dovish Fed Comments, PepsiCo Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.26% this morning as comments from Fed officials bolstered bets that the U.S. central bank may stand...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
ZS : 214.22 (-2.29%)
NOC : 460.08 (+1.14%)
LMT : 431.94 (+1.28%)
DAL : 41.57 (-1.40%)
AAL : 14.81 (-5.43%)
DDOG : 130.67 (+0.35%)
PEP : 165.37 (+0.47%)
ELIS.FP : 21.260 (+0.76%)
IMUX : 1.5300 (+5.52%)
AKRO : 31.07 (+11.72%)
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as...

IMUX : 1.5300 (+5.52%)
Immunic to Participate in Scientific Conferences in October

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.5300 (+5.52%)
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.5300 (+5.52%)
Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective...

IMUX : 1.5300 (+5.52%)
Immunic to Participate in Investor and Scientific Conferences in August

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.5300 (+5.52%)
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.5300 (+5.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 1.7500
2nd Resistance Point 1.6500
1st Resistance Point 1.5900
Last Price 1.5300
1st Support Level 1.4300
2nd Support Level 1.3300
3rd Support Level 1.2700

See More

52-Week High 3.1100
Fibonacci 61.8% 2.2830
Fibonacci 50% 2.0275
Fibonacci 38.2% 1.7721
Last Price 1.5300
52-Week Low 0.9451

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar